FOR IMMEDIATE RELEASE Contact: Neal G. Koller
President & CEO
03 August 2010 Board of Directors
+1 (434) 563-4321.
PLUROGEN RECEIVES EUROPEAN MARKETING APPROVAL
FOR PLUROGEL® with SILVER SULPHADIAZINE:
1ST SIGNIFICANT BURN & WOUND PRODUCT ADVANCEMENT IN 30 YEARS
(Charlottesville, VA, 3 August 2010) – PluroGen Therapeutics, Inc. is pleased to announce that its flagship
burn and wound gel, PluroGel® with Silver Sulphadiazine, has received European marketing approval,
opening the estimated over $2.0 billion European Advanced Wound Care market to PluroGen.
Neal G. Koller, President & CEO of PluroGen, commenting on the European approval of this advanced new
medical tool for burn and wound patients, said “Our PluroGel® with Silver Sulphadiazine is the first
significant advancement in topical burn and wound care products to be introduced in over 30 years. Our
unique PluroGel® technology solves a good number of the problems of existing competitive products,
including reducing pain for the patients while improving and reducing cost of the dressing removal and
change processes, and our inclusion of Silver Sulphadiazine provides the doctor, the nurse and the patient
with the trusted, number one topical antimicrobial. We are pleased PluroGen is able to offer this much
improved product for burn and wound patients, which comprise an over $2 billion market opportunity in
Europe alone.”
About PluroGen Therapeutics, Inc.
PluroGen is a burn, wound and skin care company commercializing our multiple patent-protected technology
platforms, the 1st of which is our core gel technology that provides superior and differentiated physical, bio-
impact and multi-function benefits. Our multiple technology platforms are configurable to deliver a wide
variety of medicinal and beneficial compounds as protected and advanced therapeutic and topical products
for simple and complex skin care and burn and wound healing. PluroGen’s product pipeline targets
improved, protected therapies for the 6 areas of treatment in tissue management and healing (cleansing,
infection, pain, inflammation, tissue salvage, tissue regeneration).
PluroGen’s first gels, PluroGel® and ActiviGel™, are being used initially in skin and wound cleansing
products, for personal skin care products and for two branded topical antimicrobial products, PluroGel®
Barrier Gels and PluroGel® Barrier Dressings. PluroGel® / ActiviGel™ technology is currently in routine
use at the University of Virginia Medical Center, having shown superior results on more than 9,000 patients
in two different patient populations, severe burns and chronic wounds. The PluroGen management and
operational teams, Boards and Principal Investigators are recognized global clinical and commercial leaders
in PluroGen’s target markets of burn and wound care and in the life sciences industry.
For more information about PluroGen Therapeutics, Inc., visit the Company’s web site at www.plurogen.com.
Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995. The Company cautions readers that forward-looking statements are
subject to certain risks and uncertainties, which could cause actual results to differ materially and which are identified from
time to time in the Company’s reports filed with the U.S. Securities and Exchange Commission. PluroGen Therapeutics, Inc.
claims the protection of the Safe Harbor for forward-looking statements contained in the Private Securities Litigation Reform
Act of 1995.
Information included on PluroGen Therapeutics, Inc website is not incorporated herein by reference or otherwise.
President & CEO
03 August 2010 Board of Directors
+1 (434) 563-4321.
PLUROGEN RECEIVES EUROPEAN MARKETING APPROVAL
FOR PLUROGEL® with SILVER SULPHADIAZINE:
1ST SIGNIFICANT BURN & WOUND PRODUCT ADVANCEMENT IN 30 YEARS
(Charlottesville, VA, 3 August 2010) – PluroGen Therapeutics, Inc. is pleased to announce that its flagship
burn and wound gel, PluroGel® with Silver Sulphadiazine, has received European marketing approval,
opening the estimated over $2.0 billion European Advanced Wound Care market to PluroGen.
Neal G. Koller, President & CEO of PluroGen, commenting on the European approval of this advanced new
medical tool for burn and wound patients, said “Our PluroGel® with Silver Sulphadiazine is the first
significant advancement in topical burn and wound care products to be introduced in over 30 years. Our
unique PluroGel® technology solves a good number of the problems of existing competitive products,
including reducing pain for the patients while improving and reducing cost of the dressing removal and
change processes, and our inclusion of Silver Sulphadiazine provides the doctor, the nurse and the patient
with the trusted, number one topical antimicrobial. We are pleased PluroGen is able to offer this much
improved product for burn and wound patients, which comprise an over $2 billion market opportunity in
Europe alone.”
About PluroGen Therapeutics, Inc.
PluroGen is a burn, wound and skin care company commercializing our multiple patent-protected technology
platforms, the 1st of which is our core gel technology that provides superior and differentiated physical, bio-
impact and multi-function benefits. Our multiple technology platforms are configurable to deliver a wide
variety of medicinal and beneficial compounds as protected and advanced therapeutic and topical products
for simple and complex skin care and burn and wound healing. PluroGen’s product pipeline targets
improved, protected therapies for the 6 areas of treatment in tissue management and healing (cleansing,
infection, pain, inflammation, tissue salvage, tissue regeneration).
PluroGen’s first gels, PluroGel® and ActiviGel™, are being used initially in skin and wound cleansing
products, for personal skin care products and for two branded topical antimicrobial products, PluroGel®
Barrier Gels and PluroGel® Barrier Dressings. PluroGel® / ActiviGel™ technology is currently in routine
use at the University of Virginia Medical Center, having shown superior results on more than 9,000 patients
in two different patient populations, severe burns and chronic wounds. The PluroGen management and
operational teams, Boards and Principal Investigators are recognized global clinical and commercial leaders
in PluroGen’s target markets of burn and wound care and in the life sciences industry.
For more information about PluroGen Therapeutics, Inc., visit the Company’s web site at www.plurogen.com.
Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995. The Company cautions readers that forward-looking statements are
subject to certain risks and uncertainties, which could cause actual results to differ materially and which are identified from
time to time in the Company’s reports filed with the U.S. Securities and Exchange Commission. PluroGen Therapeutics, Inc.
claims the protection of the Safe Harbor for forward-looking statements contained in the Private Securities Litigation Reform
Act of 1995.
Information included on PluroGen Therapeutics, Inc website is not incorporated herein by reference or otherwise.
PluroGen Therapeutics, Inc.
503 Broadleaf Way
Charlottesville, VA 22911
Tel:+1 (434) 563-4321.
Fax: 410 990 9817
www.plurogen.com
503 Broadleaf Way
Charlottesville, VA 22911
Tel:+1 (434) 563-4321.
Fax: 410 990 9817
www.plurogen.com
| News Release |
